

# ESG Index: Innovation

## Clinical trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. These studies ensure that an investigative medicine is effective and safe, and rely entirely on patients and healthy volunteers. For every Novartis clinical trial our primary responsibility is to protect the safety, well-being and legal rights of all participants and ensure adherence to the highest ethical standards for clinical research.

### Relevant links and disclosures

- [Commitment to patients and caregivers](#)
- [Clinical Study Transparency: Clinical Study Registration, Results Reporting and Data Sharing \(PDF 0.2 MB\)](#)
- [Position on Scientific Publications \(PDF 0.2 MB\)](#)
- [Commitment to Diversity in Clinical Trials \(PDF 0.1 MB\)](#)
- [Position on Investigator Initiated Trials \(IITs\) and Investigator Initiated Research \(IIRs\) \(PDF 0.2 MB\)](#)
- [Novartis Clinical Trials Results Website](#)
- [Position on Responsible Clinical Trials \(PDF 0.2 MB\)](#)
- [Ethics in Clinical Trials](#)
- [Position on Post-Trial Access \(PDF 0.2 MB\)](#)
- [Position on Collaborating with Patient Organizations \(PDF 0.2 MB\)](#)

## Innovation for neglected diseases

Under the “Access to Medicines” section please see:

- [Global health and neglected diseases](#)

We have already exceeded our pledge of USD 250 million over five years (2021- 2025) to help advance new treatments for neglected tropical diseases (NTDs) and malaria. Our cumulative investment since 2021 had reached USD 359.9 million at the end of 2024.

## Animal welfare

Animal research is key to many of the great medical advances of today, including vaccines for diseases like polio; cancer treatments; medicines to treat neurological diseases such as epilepsy, schizophrenia and depression; medicines for diseases that have high morbidity and mortality rates around the world like high blood pressure, diabetes, malaria and much more.

While the end of medical research involving animals might be a future possibility, it is not possible today. Often, animal studies are required by regulatory agencies around the world to better understand complex disease mechanisms and to prove that medicines are safe and effective.

- [Progress \(PDF 5.0 MB\)](#)
- [Animal Research website](#)
- [Animal Welfare Policy \(PDF 0.3 MB\)](#)
- [Position on animal research \(PDF 0.2 MB\)](#)

## Pandemic preparedness

As outbreaks emerge, we must contain epidemics but also prevent their subsequent development into pandemics. The availability of appropriate therapeutic interventions is a key element of a robust, holistic approach to pandemic preparedness, together with surveillance, diagnostics and preventive medical and non-medical countermeasures.

### Relevant links and disclosures

- [Pandemic preparedness](#)

## Responsible use of new technologies

[Our Commitment to ethical and responsible use Artificial Intelligence \(AI\)](#)

---

**Source URL:** <https://prod1.novartis.com/esg/index/innovation>

### List of links present in page

1. <https://prod1.novartis.com/esg/index/innovation>
2. <https://prod1.novartis.com/patients-and-caregivers/novartis-commitment-patients-and-caregivers>
3. [https://prod1.novartis.com/sites/novartis\\_com/files/clinical-trial-data-transparency.pdf](https://prod1.novartis.com/sites/novartis_com/files/clinical-trial-data-transparency.pdf)
4. [https://prod1.novartis.com/sites/novartis\\_com/files/position-on-scientific-publications.pdf](https://prod1.novartis.com/sites/novartis_com/files/position-on-scientific-publications.pdf)
5. [https://prod1.novartis.com/sites/novartis\\_com/files/commitment-for-diversity-in-clinical-trials.pdf](https://prod1.novartis.com/sites/novartis_com/files/commitment-for-diversity-in-clinical-trials.pdf)
6. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-investigator-initiated-trials.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-investigator-initiated-trials.pdf)
7. <https://www.novctrd.com/#/terms>
8. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-position-on-responsible-clinical-trials.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-position-on-responsible-clinical-trials.pdf)
9. <https://prod1.novartis.com/clinicaltrials/ethics-clinical-trials>
10. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-position-on-post-trial-access.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-position-on-post-trial-access.pdf)
11. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-position-on-collaborating-with-patient-organizations.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-position-on-collaborating-with-patient-organizations.pdf)
12. <https://prod1.novartis.com/esg/index/access-medicines#gh>
13. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-integrated-report-2024.pdf#page=45](https://prod1.novartis.com/sites/novartis_com/files/novartis-integrated-report-2024.pdf#page=45)
14. <https://prod1.novartis.com/investors/reporting-and-transparency-hub/animal-research>
15. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-global-animal-welfare-policy.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-global-animal-welfare-policy.pdf)
16. [https://prod1.novartis.com/sites/novartis\\_com/files/animal-research.pdf](https://prod1.novartis.com/sites/novartis_com/files/animal-research.pdf)
17. <https://prod1.novartis.com/esg/global-health/pandemic-preparedness>
18. <https://prod1.novartis.com/esg/ethics-risk-and-compliance/compliance/our-commitment-ethical-and-responsible-use-artificial-intelligence-ai>